Hepatocellular Carcinoma Resectable Clinical Trial
Official title:
Applicability of Patient Derived Orthotopic Xenograft (PDOX) in Patients With Primary Liver Cancer: A Randomized Controlled Trial
This Randomized Controlled Trial was to clarity the clinical feasibility of PDOX results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.
Data of Patients who received PDOX after primary liver cancer radical reaction and received Transarterial Chemoembolization #will be collected #excluding incomplete data. The primary endpoint was the one-year disease-free survival(DFS) rate #Secondary endpoint was the adverse event. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06157060 -
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
|
||
| Not yet recruiting |
NCT04850040 -
A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin
|
Phase 2 | |
| Not yet recruiting |
NCT06449846 -
Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
|
||
| Completed |
NCT06294808 -
Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC
|
||
| Recruiting |
NCT06003673 -
A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC
|
Phase 4 | |
| Completed |
NCT04177316 -
Hypermethylation of VTRNA2-1 Promoter in HCC Outcome
|